$1.55
-0.12-7.19%
Last update: Oct 30, 5:23 PM
Inhibikase Therapeutics Inc (IKT) Stock Price, Quote, News & History
IKTNASDAQ
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
Other companies in Inhibikase Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Inhibikase Therapeutics has a consensus price target of $4.94.
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $1.53 last updated October 30, 2026 at 5:23 PM EDT.
There are no upcoming dividends for Inhibikase Therapeutics.
Inhibikase Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Inhibikase Therapeutics.
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor...
